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Abstract 
Ageing phenotypes, such as years lived in good health (healthspan), total years lived (lifespan), 
and survival until an exceptional old age (longevity), are of interest to us all but require 
exceptionally large sample sizes to study genetically. Here we combine existing genome-wide 
association summary statistics for healthspan, lifespan, and longevity in a multivariate 
framework, increasing statistical power, and identified 10 genomic loci which influence all 
three phenotypes, of which five (near FOXO3, SLC4A7, LINC02513, ZW10, and FGD6) have 
not been reported previously at genome-wide significance. The majority of these 10 loci are 
associated with cardiovascular disease and some affect the expression of genes known to 
change activity with age. In total, we implicate 78 genes, and find these to be enriched for 
ageing pathways previously highlighted in model organisms, such as the response to DNA 
damage, apoptosis, and homeostasis. Finally, we identify a pathway worthy of further study: 
haem metabolism.  
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Introduction 
 
Human ageing is characterised by a progressive decline in the ability to maintain homeostasis, 
leading to the onset of age-related diseases and eventually death. However, there is much 
variation between individuals, with some experiencing chronic disease early on and dying 
before age 60, while others are able to reach an exceptional old age, often free of disease until 
the last few years of life1. A long and healthy life is determined by many different factors, 
including lifestyle, environment, genetics, and pure chance. Recent estimates suggest the 
genetic component of both human lifespan (i.e. the number of years lived) and healthspan (the 
number of years lived in good health free of morbidities) is only around 10%2,3, which makes 
genetic studies of these traits challenging, as noise tends to obscure effects unless sample sizes 
are large. 
However, with sufficiently large samples, genome-wide association studies (GWAS) of 
lifespan traits have the potential to identify genes and pathways involved in the human ageing 
process. GWAS have attempted to identify loci and pathways related to healthspan3,4, (parental) 
lifespan5–7 and survival to exceptional old age (often called longevity)8,9, with some overlap 
between findings. Multivariate analyses of correlated traits offers the prospect of increased 
power10, especially where samples do not overlap, and offers the prospect of identifying 
variants influencing a common underlying ageing process. 
Here, we assess the degree of genetic overlap between published GWAS of three different kinds 
of ageing phenotypes—healthspan, parental lifespan, and longevity (defined as survival to an 
age above the 90th percentile)—and perform a multivariate meta-analysis to identify genetic 
variants related to healthy ageing. We subsequently characterise the sex- and age-specific 
effects of loci which affect all three lifespan traits and look up reported associations with age-
related phenotypes and diseases. Finally, we link the observed signal in these loci to the 
expression of specific genes, including some that are currently studied in model organisms, and 
identify pathways involved in healthy ageing.  
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Results 
Genetic correlations between survival traits 
We explored three public, European-ancestry GWAS of overlapping ageing traits: healthspan 
(N = 300,477 individuals, 28.3% no longer healthy), parental lifespan (N = 1,012,240 parents, 
60% deceased), and longevity (Ncases = 11,262; Ncontrols = 25,483). The traits show substantial 
genetic correlations (P < 5x10–8) despite differences in age demographic, trait definition, and 
study design. Parental lifespan correlates strongly with both healthspan (rg = 0.70; SE = 0.04) 
and longevity (rg = 0.81; SE = 0.08), while healthspan and longevity show a weaker correlation 
with each other (rg = 0.51; SE = 0.09) (Figure 1a). We performed an age-stratified GWAS of 
parental lifespan in UK Biobank to assess whether the genetic correlations between the traits 
are age-dependent, but our results showed no clear trend in the correlations between 
healthspan/longevity and age-stratified lifespan bands (Figure 1b). 
 
Figure 1: Healthspan, lifespan, and longevity are highly genetically correlated. a) Pairwise genetic correlation 
between human ageing studies. b) Genetic correlations of age-stratified parental lifespan against healthspan and 
longevity. c) Genetic correlations (rg) of survival traits with traits related to development, behaviour, and disease. 
In bold are traits with heterogeneous correlations (Phet < 0.05). Displayed here are 17 traits which have at least one 
significant (FDR < 5%) genetic correlation with healthspan, lifespan, or longevity, out of the 27 traits tested. The 
17 traits are clustered by Euclidean distance based on their genetic correlation with all tested traits (30 in total). 
See Supplementary Data 1 for a full list of correlations and Supplementary Table 1 for the number of SNPs 
used to calculate each pairwise correlation. Blank squares represent correlations which did not pass multiple testing 
correction. Note that fewer correlations with longevity will pass this threshold due to the smaller sample size of 
this GWAS. Error bars represent 95% confidence intervals of the correlation estimates. COPD—Chronic 
Obstructive Pulmonary Disease. 
We next tested whether differences in survival trait genetics could be explained by differences 
in genetic correlations with 27 other traits (Supplementary Table 1). We find all three survival 
traits show similar correlations (P < 0.05/81; Phet > 0.05) with coronary artery disease (range 
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healthspan rg –0.69; SE = 0.07 to lifespan rg  –0.49; SE = 0.10), stroke (range lifespan rg = –
0.56; SE = 0.11 to healthspan rg = –0.47; SE = 0.06), chronic obstructive pulmonary disease 
(range healthspan rg = –0.45; SE = 0.04 to lifespan rg = –0.26; SE = 0.07), and years of schooling 
(range longevity rg = 0.24; SE = 0.04 to healthspan rg = 0.34; SE = 0.03). However, we also 
find evidence for differences in correlations across the traits (Phet < 0.05): healthspan correlated 
more strongly with metabolic traits (such as type 2 diabetes) than the other studies, and showed 
negative genetic correlations with depression and cancers, especially melanoma (rg = –0.25; SE 
= 0.05), which were not observed in the other datasets. Conversely, parental lifespan correlated 
uniquely with alcohol intake (rg = –0.18; SE = 0.06) and longevity showed a unique correlation 
with Alzheimer’s disease (rg = –0.43; SE = 0.11). (Figure 1c; Supplementary Data 1). 
Genome-wide multivariate meta-analysis 
Given the correlations amongst the traits, a combined MANOVA offered the prospect of 
increased power. We therefore performed a meta-analysis of GWAS of healthspan, parental 
lifespan, and longevity, which identified 24 loci at genome-wide significance (P < 5 x 10-8) 
(Figure 2; Supplementary Data 2; Full summary statistics at https://doi.org/10.7488/ds/2793). 
The combined statistics had an LD-score regression intercept of 1.064 (SE 0.009). This suggests 
limited inflation due to population stratification or relatedness and, in line with some previous 
studies11,12, we did not adjust our statistics for this intercept. The APOE locus contained the 
most significant multivariate SNP (P < 1x10–126), associated with an average increase in lifespan 
of 12.7 months per allele (95% CI 11.4–14.0) and an increased odds ratio of reaching longevity 
of 1.66 (1.56–1.77). However, noting that <2% of the healthspan study sample experienced 
Alzheimer’s disease, the same allele was associated with an average healthspan increase of only 
around 50 days (2–98). 
 
Figure 2: Twenty-four multivariate loci identified at genome-wide significance. Manhattan plot showing the 
nominal strength of association –log10(P value) (two-sided) on the y-axis against the chromosomal position of 
SNPs on the x-axis, where the null hypothesis is no association with healthspan, parental lifespan, and longevity. 
The red line represents the genome-wide significance threshold (5x10–8). Annotated are the nearest gene(s) to the 
lead SNP (in red) of each locus. The y-axis has been capped at 5x10–30 to aid legibility; SNPs passing this cap are 
represented as triangles: LPA P=3.8x10–30, APOE P=9.6x10–127. 
 
Twenty-one of the 24 multivariate GWAS loci reaching genome-wide significance had 
directionally consistent effects in the three studied datasets and 18 were nominally significant 
(P < 0.05) in two or more datasets (Supplementary Figure 1). A look-up of the lead SNPs and 
close proxies in the GWAS catalog and PhenoScanner showed that healthspan-specific loci (i.e. 
P < 0.05 only in the healthspan dataset) were mostly associated with skin cancers and metabolic 
traits, while lifespan-specific loci were associated with smoking and risk taking 
(Supplementary Data 3). Associations with these phenotypes suggests these variants influence 
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(behaviours leading to) environmental exposures and thus likely capture extrinsic ageing 
processes. As we were primarily interested in genetic variation influencing the intrinsic ageing 
process, we focused the remainder of this study on genetic variants reaching nominal 
significance in all three datasets, which are less likely to be associated to study- or population-
specific exposures. 
Ten loci reached nominal significance (P < 0.05) in all ageing studies (Table 1). Five of these 
are of particular interest as they contain no genome-wide significant SNPs in any individual 
dataset. The lead multivariate SNP of these loci include rs2643826 (nearest gene SLC4A7), 
rs17499404 (LINC02513), rs1159806 (FOXO3), rs61905747 (ZW10), and rs12830425 (FGD6) 
(Supplementary Figures 2-6). The lead SNP near FOXO3 is in moderate linkage 
disequilibrium (LD) (r2 > 0.4) with rs2802292, a well-known candidate SNP from longevity 
studies 13. Given that some of the loci show P values near the genome-wide significance 
threshold (i.e. SLC4A7 and LINC02513), replication of these loci in large independent cohorts, 
which were not yet available to us, is warranted. 
Nearest 
Gene rsID A1 Freq1 βhealthspan Phealthspan βlifespan Plifespan βlongevity Plongevity PMANOVA 
SLC4A7 rs2643826 C 0.55 
0.021 
(0.005) 2E-05 
0.017 
(0.004) 2E-05 
0.045 
(0.020) 3E-02 4E-08 
LINC02513 rs17499404 A 0.54 
0.017 
(0.005) 7E-04 
0.012 
(0.004) 2E-03 
0.084 
(0.019) 1E-05 4E-08 
FOXO3 rs1159806 T 0.35 
0.014 
(0.005) 5E-03 
0.015 
(0.004) 2E-04 
0.095 
(0.020) 3E-06 1E-08 
ZW10 rs61905747 A 0.82 
0.029 
(0.006) 2E-06 
0.024 
(0.005) 2E-06 
0.066 
(0.026) 1E-02 4E-10 
FGD6 rs12830425 G 0.07 
0.044 
(0.009) 3E-06 
0.032 
(0.007) 2E-05 
0.077 
(0.036) 3E-02 8E-09 
LPA rs10455872 A 0.93 
0.057 
(0.009) 1E-10 
0.076 
(0.007) 9E-25 
0.124 
(0.045) 7E-03 4E-30 
CDKN2B-
AS1 rs7859727 C 0.51 
0.031 
(0.005) 3E-10 
0.025 
(0.004) 1E-10 
0.066 
(0.019) 6E-04 4E-18 
TOX3 rs4783780 A 0.53 
0.023 
(0.005) 2E-06 
0.014 
(0.004) 3E-04 
0.052 
(0.019) 6E-03 1E-08 
LDLR rs6511720 T 0.12 
0.015 
(0.007) 4E-02 
0.034 
(0.006) 2E-08 
0.093 
(0.030) 2E-03 4E-09 
APOE rs429358 T 0.85 
0.014 
(0.007) 4E-02 
0.106 
(0.005) 3E-83 
0.510 
(0.032) 1E-56 1E-126 
 
Table 1: Ten loci act across all three ageing traits, reaching nominal significance in each dataset. Nearest 
gene—Gene closest to the index SNP; rsID—The SNP with the lowest P value in the multivariate analysis; A1—
the effect allele, increasing healthspan, lifespan, and odds to become long-lived; Freq1—Frequency of the A1 
allele. β—Effect size of the A1 allele with the standard error in parentheses. For healthspan and lifespan units are 
the negative log of the hazard ratio, for longevity this is the log odds of reaching an exceptional old age (90th 
percentile). P—P value of the trait association. For MANOVA, this is the P value against the null hypothesis of 
association with neither healthspan, lifespan, nor longevity. In bold are loci which contain SNPs that are not 
reported at genome-wide significance in any individual dataset. The remaining loci contain one or more genome-
wide significant SNPs within 500 kb of the lead SNP in one of the individual datasets (Supplementary Data 4). 
Links with sex, age and age-related disease 
We next tested whether loci of interest displayed varying effects on lifespan by sex, using sex-
specific parental GWAS summary statistics from Timmers et al.7. We find evidence of sexual 
dimorphism for the ApoE ε4 allele (βfathers= 0.08, βmothers= 0.13, Pdiff < 1.5x10–6) and evidence 
of no sexual dimorphism for lead SNPs near LINC02513, SLC4A7, LPA, TOX3, and FOXO3 
(<20% difference or Pdiff > 0.50). For the remaining loci near CDKN2B-AS1, ZW10, FGD6 and 
LDLR, effect size point estimates may differ by more than 20%, but we would need a larger 
sample size to be able to detect this difference with confidence (Supplementary Figure 7). 
Looking up the same SNPs in our age-stratified parental lifespan GWAS, we find that all loci, 
except APOE and SLC4A7, show a downward trend in effect size with parental age. This trend 
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is significant for the APOE locus (Padjusted = 0.01), with the effect size of the ε4 allele increasing 
by 32% (25%–39%) for every 10-year increase in parental survival. While we are 
underpowered to confirm the trends for the remaining loci, we find that, collectively, the 
average effect of the protective alleles of these nine loci decreases by 24% (13%–34%; Padjusted  
= 1x10–4) for every 10-year increase in parental survival (Supplementary Figure 8). 
We also found loci of interest had previously been associated at a genome-wide significant level 
with several age-related diseases and/or phenotypes. The life-extending allele of the majority 
of loci is associated with a reduction in cardiovascular disease phenotypes, including SNPs near 
the ageing loci SLC4A7, FGD6, and LINC02513 discovered in this study. Interestingly, 
protective variants near FOXO3 are associated with a reduction in metabolic syndrome but also 
a reduction in cognitive ability. Life-extending SNPs near APOE, FOXO3 and FGD6 are all 
associated with increased measures of macular degeneration (Supplementary Figure 9; 
Supplementary Data 3). 
Ageing genes and pathways 
Assessing the loci of interest for colocalisation with gene expression signals (eQTL), we find 
strong evidence (FDRSMR < 5%; PHEIDI > 1%; see Methods) of cis-acting eQTL colocalisation 
for eight out of 10 loci. In total, we highlight 28 unique genes acting across 32 tissues, especially 
whole blood (12 genes) and the tibial nerve (7 genes) (Supplementary Data 5). In blood, 
higher expression levels of BCL3 and CKM (near APOE); CTC-510F12.2, ILF3, KANK2 and 
PDE4A (near LDLR); USP28 and ANKK1 (near ZW10); and CDKN2B are linked to an increase 
in multivariate lifespan traits, while the opposite is true for EXOC3L2 (near APOE), TTC12 
(near ZW10), and FOXO3. For the multivariate signal near SLC4A7 we find colocalisation of 
NEK10 (liver); for the signal near LPA we find SLC22A1/A3 (multiple tissues) and MAP3K4 
(pituitary); and for the signal near FGD6 we find FGD6 itself (adipose/arterial). Including trans-
acting eQTL from blood while keeping the same thresholds for colocalisation, we additionally 
discover higher expression levels of FOXO3B colocalises with the life-extending signal near 
FOXO3. When we include genes which could not be tested for heterogeneity (NeQTL < 3), we 
identify one additional cis-acting and 49 additional trans-acting genes (of which 10 colocalise 
with the signal near LINC02513) (Table 2; Supplementary Data 5). 
Locus Chr Position Cis-Genes Trans-Genes 
SLC4A7 3 27562988 NEK10- 
 
LINC02513 4 38385479 
 
EDAR+, MAL+, NOSIP+, CCR7+, 
ABLIM1+, KRT72+, FHIT+, MMP28+, 
EPHX2+, LEF1+ 
FOXO3 6 109006838 LINC00222-, FOXO3- FOXO3B+, MEGF6+, CALCOCO1+, 
CYBRD1+, IGF1R+, PHF21A+, NDRG1+, 
KIAA1324-, FCHO2+, CNNM3+ 
LPA 6 161010118 SLC22A1+, SLC22A3-, AL591069.1-, 
MAP3K4- 
 
CDKN2B-AS1 9 22102165 CDKN2B+ 
 
ZW10 11 113639842 USP28+, ANKK1+, TTC12-, RP11-
159N11.4-, ANKK1- 
 
FGD6 12 95580818 RP11-256L6.3+, FGD6- 
 
LDLR 19 11202306 CTC-510F12.2+, KANK2+, SPC24+, 
SLC44A2+, ILF3+, ILF3-AS1-, DOCK6-, 
SMARCA4-, PDE4A+ 
AHSP-, SELENBP1-, EPB42-, SLC4A1-, 
HBD-, CA1-, FAM46C-, BLVRB-, TMOD1-, 
GYPB-, UBE2O-, BPGM-, TRIM58-, SNCA-, 
IFIT1B-, FECH-, GMPR-, EPB49-, RBM38-, 
TNS1-, MICAL2-, DCAF12-, RAB3IL1-, 
PDZK1IP1-, HBM-, BCL2L1-, PLEK2-, 
E2F2-, TGM2- 
APOE 19 45411941 EXOC3L2-, AC006126.4+, CKM+, BCL3+, 
PVRL2+ 
LDLR- 
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Table 2: eQTL for 78 genes colocalise with the GWAS signal at 9 out of 10 loci of interest. Genes which 
showed a significant effect (FDR < 5%) of gene expression on ageing traits are displayed here. Locus—Nearest 
gene to lead variant in the multivariate analysis. Chr—Chromosome. Position—Base-pair position of lead variant 
(GRCh37). Cis-Genes—Genes in physical proximity (<500 kb) to the lead variant of the locus which colocalise 
with the multivariate signal. Trans-Genes—Genes located more than 500 kb from the lead variant of the locus. 
Gene names are annotated with the direction of effect, where + and – indicate whether the life-extending 
association of the locus is linked with higher or lower gene expression, respectively. 
 
To determine the age-related expression of the identified cis- and trans-acting genes, we 
performed a look-up in the dataset of Peters et al.14. This large dataset contains the associations 
of genes with age in whole blood, so we limited ourselves to the cis- and trans-acting genes 
identified in the whole-blood datasets. We found that FOXO3 expression is increased with age 
in this dataset, which is in line with the life-extending variant decreasing expression 
(Supplementary Data 6). Moreover, one cis- (ILF3) and two trans-acting genes (E2F2 and 
PDZK1IP1) in the LDLR locus show a similar effect (i.e. increased or decreased expression 
with age combined with the life-extending variant decreasing or increasing expression, 
respectively). The most interesting, however, seems to be the LINC02513 locus, which showed 
multiple trans-acting genes to be strongly downregulated with age while the lead life-extending 
variant increases expression. LEF1, CCR7, and ABLIM1 even belong to the most significantly 
affected genes in the whole transcriptomic dataset. This indicates that this long intergenic non-
protein coding RNA may serve as a master regulator of age-related transcription in whole blood. 
Finally, testing the full list of cis- and trans-acting genes for gene set enrichment in 50 hallmark 
and 7350 biological process pathways, we find significant enrichment (Padjusted < 0.05) in seven 
hallmark gene sets and 32 biological processes. The hallmark gene sets with the strongest 
enrichment include haem metabolism, hypoxia, and early oestrogen response (Figure 3). 
Enriched biological pathways cluster into categories involving apoptotic signalling, chemical 
homeostasis, and development of erythrocytes and myeloid cells, among others 
(Supplementary Figure 10; Supplementary Data 7). 
 
Figure 3: Seven hallmark gene pathways are enriched for ageing-related genes. N—number of genes of 
interest vs. total number of genes in the gene set for which eQTL are available. P—Nominal P value of the 
hypergeometric test for enrichment (against 24,670 background genes). Pbonf—Bonferroni-corrected P value for 
testing seven hallmark pathways (containing at least 3 genes). The figure shows individual genes on the x-axis and 
hallmark pathways are listed on the y-axis, matching the order of the table. Squares represent the presence of a 
gene in the gene set. 
Mendelian randomisation of iron traits 
We hypothesised that the effect of haem metabolism and chemical homeostasis on healthspan, 
lifespan, and longevity may be mediated through the bioavailability of iron and investigated 
this hypothesis using MR of GWAS summary statistics of iron-related traits, i.e. serum iron, 
log ferritin, and transferrin (percentage saturation and absolute levels), against our GWAS 
 8
results. In a univariate MR framework, we find evidence of a causal effect for serum iron (FDR 
< 5%), which appears to be consistent with the MR assumptions and is robust to outliers 
(Supplementary Figure 11; Supplementary Tables 2 and 3). We also find some evidence for 
an effect of transferrin saturation. However, this association is primarily driven by the well-
known hereditary haemochromatosis locus and shows evidence of violating the pleiotropy 
assumption (i.e. non-zero MR-Egger intercept). We therefore tested all iron traits as exposures 
simultaneously in a multivariate MR analysis, with our GWAS as the outcome, finding more 
reliable evidence for causal effects (FDR < 5%; βintercept = 0.001; -0.001–0.003) of serum iron, 
transferrin levels, and transferrin saturation. These effects are not driven by only one of the loci, 
including the hereditary haemochromatosis locus, as confirmed by leave-one-out analyses 
(Supplementary Data 8). Although the units of the causal effects are consistent across 
exposures (and pertinent for P values), they are difficult to interpret. We therefore repeated the 
procedure for the individual component traits: healthspan, lifespan, and longevity, recognising 
the reduction in effective sample size was likely to yield underpowered effect size estimates, 
although these give a sense of direction and magnitude of the effect in measurable units (Table 
3). Multivariate MR effect sizes appear larger than those of the univariate MR, likely due to 
homeostasis, i.e. variation in one exposure is normally buffered by another. For example, 
oxidative damage from serum iron may largely be prevented when the metal is bound to 
transferrin. 
 
Exposure βMR SE P Padj βhealthspan βlifespan βlongevity 
Serum iron -0.79 0.242 1E-03 4E-03 -1.10 (0.58) -1.17 (0.63) -5.07 (2.42) 
Transferrin saturation 0.80 0.252 1E-03 4E-03  1.11 (0.61)  1.16 (0.66)  5.15 (2.52) 
Transferrin 0.32 0.100 2E-03 4E-03  0.48 (0.24)  0.46 (0.26)  2.02 (1.00) 
Ferritin -0.01 0.024 0.5380 1.0000  0.13 (0.06) -0.02 (0.06) -0.26 (0.24) 
 
Table 3: Multivariate MR of iron-related traits on healthspan, lifespan, and longevity shows a protective 
effect for transferrin and a deleterious effect for serum iron. The effects of 15 SNPs genome-wide significant 
for one or more iron-related traits were tested against the effects of our GWAS meta-analysis and individual 
healthspan, lifespan, and longevity GWAS in an inverse variance-weighted regression. βMR —The causal effect of 
one standard deviation increase in the exposure on the healthspan/lifespan/longevity meta-analysis (in standard 
deviation units), conditional on the other exposures. P—Nominal P value for the MR effect. Padj—Multiple testing-
corrected P value. βhealthspan, βlifespan, βlongevity—The conditional effect of one standard deviation increase in the 
exposure on healthspan (in -logHR units), lifespan (in -logHR units), or longevity (in logOR units), with the 
standard error reported in parentheses. Coefficients are derived from a model with a fixed regression intercept, as 
a sensitivity analysis showed a non-significant intercept centred around zero for all traits (Pintercept ≥ 0.76). Although 
the causal effect sizes appear large, in practice, homeostatic effects prevent large variation in one of the exposures 
independent of the others. 
Discussion 
Genetic correlations between publicly available healthspan, parental lifespan, and longevity 
GWAS reveal these traits share 50% or more of their underlying genetics. Performing a 
multivariate meta-analysis on the GWAS summary statistics, we highlight 24 genomic regions 
influencing one or more of the traits. Ten regions are of particular interest as they associate with 
all three ageing traits and are as such likely candidates to capture intrinsic ageing processes, 
rather than extrinsic sources of ageing. Five of the loci of interest are not associated at a 
genome-wide significant level in any individual dataset, including the region near FOXO3 
which has thus far only been highlighted in candidate gene association studies (reviewed in 
Sanese et al.15) and never at genome-wide significance. The effects of loci of interest on male 
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and female lifespan are largely the same, although their effect on survival may be slightly 
stronger in middle age (40–60) compared to old age (80+). The ApoE ε4 allele is exceptional 
in this regard as its effect is stronger in females and increases with age, likely due to its well-
known link to Alzheimer’s disease16. We find these loci of interest colocalise with the 
expression of 28 cis-genes and 50 trans-genes, some of which are known to become 
differentially expressed with increasing age. Lastly, we find these genes are enriched for seven 
hallmark gene sets (particularly haem metabolism) and 32 largely overlapping biological 
pathways (including apoptosis and homeostasis), and in line with the highlighted pathways, we 
find a causal role for iron levels in healthy life in a MR framework. 
Interpretation of MR results should be treated with some caution and transparency of the applied 
method as well as a sensitivity analysis are necessary17. In summary, we used an inverse-
variance weighted approach in a two-sample MR setting using independent GWAS summary 
statistics to provide corroboration for the haem metabolism finding (see Methods). The sample 
overlap between iron-related GWAS and our study was <2.5%. The instrumental variables were 
independent genome-wide significant SNPs (P < 5x10–8), supported by knowledge of biological 
plausibility as they included several iron transporters and the hereditary haemochromatosis 
locus, the latter of which had the greatest effect on iron in line with expectations18. The causal 
effect of iron is further supported by two sensitivity analyses: one showing no evidence of 
pleiotropy (MR-Egger) and the other showing the observed effect is robust to exclusion of 
outliers (leave-one-out). 
The antagonistic pleiotropy and hyperfunction theories of ageing predict the presence of genetic 
variants important for growth and development in early life with deleterious effects towards the 
end of the reproductive window19,20. While we are unable to directly capture the genetic effects 
on individuals before age 40 due to the study design of our datasets, we found the life-extending 
variant near FOXO3 is associated with a delay in the age at menarche and a decrease in 
intracranial volume and cognitive abilities. It thus appears that there are loci exhibiting 
antagonistic effects, although we are unable to discern whether this is due to true pleiotropy or 
due to linkage of causal variants within a region of LD. Should the former be true, this would 
add to existing evidence for antagonistic pleiotropy in humans, which includes two recent 
studies that showed antagonistic pleiotropic effects for genes involved in coronary artery 
disease21 and ageing22. However, almost all loci of interest associate strongly with 
cardiovascular and blood cell phenotypes, without apparent antagonistic effects, in line with 
established knowledge that cardiovascular disease is a leading cause of mortality and morbidity 
worldwide23.  
Several of the genes we identify have previously been shown to influence lifespan in 
experiments on model organisms. For example, knockouts of the orthologs of APOE, LDLR, 
CDKN2B, and RBM38 in mice shortens their lifespan24–27, while knockout of IGF1R has the 
opposite effect28. Similarly, overexpression of the FOXO3 orthologue in Drosophila 
melanogaster29 and the SNCA orthologue in Caenorhabditis elegans30 have shown to extend 
their respective lifespans as well. Many of our genes are also enriched for pathways previously 
related to ageing in eukaryotic model organisms, including genomic stability, cellular 
senescence, and nutrient sensing31. For example, FOXO3 and IGF1R are well-known players 
modulating survival in response to dietary restriction32, but we also highlight genes involved in 
the response to DNA damage and apoptosis, such as CDKN2B, USP28, E2F2, and BCL3. In 
addition to hallmarks discovered in model organisms, our results suggest that haem metabolism 
may play a role in human ageing. This pathway includes genes involved in processing haem 
and differentiation of erythroblasts33. Although the enrichment is largely driven by genes linked 
to the LDLR locus, genes linked to other loci of interest (such as FOXO3, CDKN2B, 
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LINC02513) are involved in similar biological pathways: myeloid differentiation, erythrocyte 
homeostasis, and chemical homeostasis. 
The pathway analysis has potential limitations due to the correlative nature of the genes used 
to test for enrichment, which can inflate type 1 errors34. However, the strong signal for haem 
metabolism, in combination with the MR results, suggests the evidence for the involvement of 
this pathway in human ageing is reasonably robust. Haem synthesis declines with age and its 
deficiency leads to iron accumulation, oxidative stress, and mitochondrial dysfunction35. In 
turn, iron accumulation helps pathogens to sustain an infection36, which is in line with the 
known increase in infection susceptibility with age37. In the brain, abnormal iron homeostasis 
is commonly seen in neurodegenerative diseases such as Alzheimer’s, Parkinson’s and multiple 
sclerosis38. Plasma ferritin concentration, a proxy for iron accumulation when unadjusted for 
plasma iron levels, has been associated with premature mortality in observational studies39, and 
has been linked to liver disease, osteoarthritis, and systemic inflammation in MR studies40,41. 
A particular strength of this study is the ability to identify loci shared by multiple traits, without 
the need for additional sample collection. Comparing the strength of the multivariate 
association at our 10 loci of interest with the strength of association within each individual 
GWAS, we estimate the combined statistics are equivalent to a median sample size increase of 
127% (95% CI 52%–728%; ~380,876 individuals) for the healthspan study, 76% (23%–146%; 
~768,578 parents) for the parental lifespan study, and 415% (59%–620%; ~64,810 cases) for 
the longevity study. This gain in power is particularly important for the latter since the sample 
size of GWAS for longevity will likely not improve in the near future due to limited availability 
of data on long-lived people. Having demonstrated the advantages of jointly studying three 
ageing traits, we encourage future studies to incorporate additional large-scale age-related trait 
GWAS, such as a recent study on frailty in UK Biobank42, to further improve power. 
It is clear from the association of age-related diseases and the well-known ageing loci APOE 
and FOXO3 that we are capturing the human ageing process to some extent; however, some 
judgment is involved in definitions. For one, there are currently no widely accepted standards 
for measuring healthspan43. Zenin et al.3 define healthspan based on the incidence of the eight 
most common diseases increasing exponentially in incidence with age in their sample. As such, 
their trait is highly dependent on the characteristics of the UK Biobank cohort, who were aged 
40–69 years when they were recruited in 2006–2010 and of which two-thirds have yet to 
experience an age-related disease. Therefore, loci with effects on diseases of middle age (cancer 
and heart disease) are likely overrepresented in our analysis. The lack of Alzheimer’s disease 
in the UK Biobank sample also explains the limited association of APOE in the healthspan 
GWAS, compared to the other ageing traits. Similarly, the lifespan GWAS is dependent on the 
most common causes of death in the parental generation. As such, the observed cardiometabolic 
associations may, to some extent, reflect the large effect of these diseases on death in Europe a 
few decades ago. Future studies on additional cohorts with wider age ranges, disease 
frequencies, and causes of death (including individuals of non-European ancestries) would be 
able to show if loci shared between ageing traits are indeed independent from cohort-specific 
characteristics and reflect common biological ageing mechanisms.  
Multivariate analysis of traits does not provide a natural combined effect size or direction of 
effect. Colocalisation of eQTL with loci of interest requires effect directions to test for 
heterogeneity of instruments. As such, we used the direction of the sum of the Z scores of the 
underlying traits to assign a direction to Z scores derived from MANOVA P values. This works 
well for SNPs with concordant effects on ageing traits but is less accurate when SNPs have 
heterogeneous or antagonistic effects. For example, a SNP associated with an increase in 
healthspan and an equal decrease in lifespan—while likely rare—will have a large Z score in 
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the MANOVA, but no clear direction of effect. This limitation will introduce some 
heterogeneity in the colocalisation analysis, and as a result inflate the HEIDI statistic. 
Furthermore, gene expression colocalisation is limited by the number of tissue eQTL (with 
some tissues being underpowered) and does not capture the effect of coding variation. There 
may be additional genes with highly tissue-specific effects or effects dependent on structure or 
splicing isoforms, which we are unable to detect. 
The pathways we have highlighted mostly relate to biological processes for chemical and 
cellular homeostasis and are therefore likely to be generalisable across populations; however, 
it is important to note that all GWAS summary statistics used in our study were derived from 
individuals of European ancestry and more follow-up work is necessary to validate our findings 
in individuals from other ethnic backgrounds. For example, certain population characteristics, 
such as levels of obesity and meat intake can affect the bioavailability of iron44 and thus the 
relative importance of haem metabolism in ageing. 
Another limitation is that our meta-analysis, like many others, is focused on the identification 
of additive genetic variants. The evolutionary theory of ageing predicts that recessive variants 
may have larger effects on fitness45, and this prediction is supported by a recent study on the 
relation between recessive mutations involved in haemochromatosis and morbidity41. 
Heritability studies of lifespan show that a small but significant amount of phenotypic variation 
may be explained by dominance effects46, and, as such, future studies should also try to study 
the effect of recessive variants on ageing traits.  
Importantly, the genes we have highlighted show natural variation in the human population and 
some of them show altered levels of expression with increasing age, which make them good 
candidates for therapeutic intervention. However, colocalisation of gene expression could be 
due to pleiotropy rather than causality, and there is a need to validate the effects of genetic 
variants in experimental models to confirm their role in disease aetiology. For example, we 
have found life-extending variants colocalise with decreased expression of FOXO3 in blood, 
which itself becomes increasingly expressed with increasing age, but experiments suggest the 
gene has many protective functions including detoxification of reactive oxygen species and 
DNA damage repair15. The observed inverse relationship between healthy life and FOXO3 
expression may reflect healthy individuals have less oxidative damage and require less FOXO3 
to mitigate this damage. 
In conclusion, the challenge of studying ageing genetics in humans—low heritability and 
limited samples—can be overcome to some extent by combining large studies of closely related 
phenotypes that capture elements of ageing process. Focusing on the overlap between different 
populations and age-related traits has revealed that several ageing pathways discovered in 
model organisms also apply to humans, and has highlighted genes and pathways in humans 
which can now be further tested in model organisms. This study, and follow-up work on the 
genes we have highlighted, will eventually lead to therapeutic targets that can reduce the burden 
of age-related diseases, extend the healthy years of life, and increase the chances of becoming 
long-lived without long periods of morbidity. 
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Methods 
Data sources 
We downloaded three publicly available sets of summary statistics on healthspan47 
(http://doi.org/10.5281/zenodo.1302861), parental lifespan48  
(http://dx.doi.org/10.7488/ds/2463), and longevity9 
(https://www.longevitygenomics.org/downloads), whose derivation is briefly described here. 
Healthspan 
The Healthspan GWAS consists of 300,477 unrelated, British-ancestry individuals from UK 
Biobank. The statistics were calculated by fitting Cox-Gompertz survival models with events 
defined as the first incidence of one of seven diseases (any cancer, diabetes, myocardial 
infarction, stroke, chronic obstructive pulmonary disease, dementia, and congestive heart 
failure) or death itself. Martingale residuals from this model were then regressed against HRC-
imputed dosages. Of the 84,949 individuals who had experienced an event (and thus had 
complete healthspans), 51.3% experienced a cancer event, 18.0% a diagnosis of diabetes and 
17.1% a myocardial event. Less than 5% of the individuals experienced their first event due to 
one of the remaining diseases. See Zenin et al.3 for details. After removing single nucleotide 
polymorphisms (SNPs) with duplicate rsIDs (N = 19,386) summary statistics were available 
for 5,429,268 common (MAF ≥ 0.05) and 5,860,562 rare (MAF < 0.05) SNPs.  
Lifespan 
The Parental Lifespan GWAS consists of unrelated, European-ancestry individuals reporting a 
total of 512,047 mother and 500,193 father lifespans, of which 60% were complete. The 
statistics for each participating cohort were calculated by fitting Cox survival models to father 
and mother survival separately, adjusted for subject sex, at least 10 principal components, and 
study-specific covariates such as genotyping batch and array. Martingale residuals of the 
survival models were regressed against subject dosages (HRC-imputed). Father and mother 
results were combined into two separate ways: father and mother residuals from UK Biobank 
were combined before regression, while father and mother summary statistics from other 
cohorts were meta-analysed, adjusting for the phenotypic correlation between parents. See 
Timmers et al.7 for details. Summary statistics were available for 5,526,246 common (MAF ≥ 
0.05) and 3,559,402 rare (MAF < 0.05) SNPs. 
Longevity 
The Longevity GWAS consist of unrelated, European-ancestry individuals who lived to an age 
above the 90th survival percentile (Ncases = 11,262) or whose age at the last follow-up visit (or 
age at death) was at or before the 60th percentile age (Ncontrols = 25,483). The statistics for each 
of the participating cohorts were calculated using logistic regression and 1000G Phase 1 version 
3-imputed dosages, adjusted for clinical site, known family relationships, and/or the first four 
principal components (if applicable) and subsequently combined using a fixed-effect meta-
analysis. See Deelen et al.9 for details. After removing SNPs with duplicate IDs (N = 17,152), 
summary statistics were available for 6,657,238 common (MAF ≥ 0.05) and 2,181,962 rare 
(MAF < 0.05) SNPs. 
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Age-stratified survival analysis 
We carried out a series of additional, age-stratified GWAS using a sample of 325,614 unrelated, 
British-ancestry individuals from UK Biobank (as determined by genomic PCA and 3rd degree 
kinship or closer)49, in order to calculate age band-specific effects of SNPs on lifespan. These 
individuals answered questions regarding their family history via touchscreen questionnaire, 
including their adoption status and parental age or age at death if deceased. Quality control was 
performed in R version 3.6.0 as in Timmers et al.7, starting with 409,692 British-ancestry 
individuals and excluding subjects who were adopted, had two parents who died before age 40, 
or who did not provide information on parental age (N = 12,406; 3.0%). Additionally, we 
excluded individuals who had withdrawn their consent to participate as of 16 October 2018 and 
all but one of each related set of individuals (N = 71,672; 17.5%). Related individuals were 
excluded as mixed modelling is not well understood in the context of the kin-cohort method7. 
The remaining 325,614 individuals reported 312,088 and 322,672 father and mother lifespans, 
respectively, of which 67.7% were complete. Parent lifespans were then split into three age 
bands, 40–60, 60–80, and 80–120, excluding parents who died before the start of the age band 
and treating any parent who survived at least until the end of the age band as alive (i.e. right-
censored). Sample descriptives of each age band are detailed in Supplementary Table 4. Using 
the R package survival, Cox proportional hazard models were fitted separately to each father 
and mother age band—six combinations in total—adjusted for subject sex, genotyping batch 
and array, and the first 40 genetic principal components.  
ℎ(𝑥) = ℎ଴(𝑥)eఉభ𝐗𝟏ାఉమ𝐗𝟐ା...ାఉ೙𝐗𝒏 (1) 
Where h(x) is the hazard of the parent at age x, h0(x) the baseline hazard, and β1, β2, …, βn the 
effect sizes (natural log of the hazard ratio) associated with the covariates X1, X2, …, Xn. 
Martingale residuals of these models were taken50, divided by the proportion dead to scale 
effects to hazard ratios and doubled to account for parental genotype imputation5, and then 
regressed against subject allelic dosage in an additive model using RegScan51. Individual 
parental lifespan statistics were combined using inverse-variance meta-analysis, inflating 
standard errors by ඥ1 + 𝑟୮ to take into account the correlation between the parental phenotypes 
(rp). 
Genetic correlation analysis 
LD-score regression52 was used to calculate genetic correlations between ageing trait GWAS, 
age-stratified parental lifespan (described above) and 27 European-ancestry GWAS of 
developmental, behavioural, and disease traits (Supplementary Table 1). In line with 
recommendations53, imperfectly imputed (INFO < 0.9) and low frequency (MAF < 0.05) SNPs, 
as well as those located in the Major Histocompatibility Complex, were discarded before 
merging the summary statistics with a HapMap3 reference panel to reduce statistical noise. An 
average of 1,086,952 SNPs (range 866,405–1,181,238) were used to calculate genetic 
correlations per set of summary statistics, based on LD-score regression weights derived from 
European individuals. 
Multivariate genomic scan 
Healthspan, parental lifespan, and longevity summary statistics were meta-analysed using 
MANOVA, while accounting for correlations between studies due to (limited) sample overlap 
and correlation amongst the traits, as implemented in MultiABEL v1.1-610. Correlations were 
calculated from summary statistics by taking the correlation in effect estimates from 
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independent SNPs between studies (60,338 default SNPs provided by MultiABEL and shared 
between studies). These correlation estimates ranged from 0.013 between healthspan and 
longevity to 0.094 between healthspan and parental lifespan, reflecting a small degree of sample 
overlap and/or phenotypic correlation. Summary association statistics were calculated for the 
7,320,282 SNPs shared between studies, of which 5,278,109 were common (MAF ≥ 0.05) and 
2,042,173 were rare (MAF < 0.05). These statistics represent the significance of each SNP 
affecting one or more of the traits, giving a P value against the null hypothesis that effect sizes 
are zero in all studies. The method does not provide a combined effect size. 
Loci were defined as 500 kb regions flanking the lead genome-wide significant SNP in linkage 
equilibrium (r2 < 0.1) with other lead SNPs. LD-score regression was used to assess inflation 
of the GWAS statistics, using 1,138,687 SNPs from the MANOVA and LD weights from 
European samples from the 1000 Genomes project. Loci with lead SNPs showing a nominally 
significant effect (P < 0.05) in all three datasets were considered more likely to capture intrinsic 
ageing pathways. We refer to them as loci of interest throughout this study. 
Sex- and age-stratified analyses 
Lead SNPs of loci of interest were looked up in individual father and mother survival statistics 
from Timmers et al.7. Differences in the parental effect sizes were tested using (βfathers–
βmothers)/sqrt(SEfathers2 + SEmothers2), where SE is the standard error of the effect estimate. This 
statistic follows a Z distribution, assuming errors in measured effects are independent. 
Age-specific survival statistics were retrieved for the same loci from our age-stratified parental 
lifespan GWAS in UK Biobank. In order to standardise effects for each locus, we expressed the 
age-specific effect as a fold change from the unstratified effect in UK Biobank, inflating 
standard errors using the Taylor series expansion to account for the uncertainty in the 
denominator: 
𝛼 = ఉౘ౗౤ౚ
ఉ౗ౢౢ
− 1 (2) 
SEఈ = ඨ
ୗ୉మౘ౗౤ౚ
ఉమ౗ౢౢ
+ ఉ
మ
ౘ౗౤ౚୗ୉మ౗ౢౢ
൫ఉమ౗ౢౢ൯
మ  (3) 
Where α is the fold change in effect, βband is the effect estimate of the age-specific band, βall is 
the unstratified effect estimate, and SE is the standard error of the respective effects.  
This provided a relative change in effect size per parental age band. We then calculated the 
median survival from Kaplan-Meier survival curves of each age band, allowing us to place the 
effects on a years-of-life scale. For each locus individually, effect sizes of age bands were 
regressed against median survival of the age band, inversely weighted by the variance of the 
effect estimate (constituting 10 statistical tests). Coefficients of the loci underpowered to detect 
a trend individually (P > 0.05/10) were meta-analysed, again weighted by the inverse of their 
variance, to provide a collective estimate. A sensitivity analysis examining the collective trend 
estimate using all loci of interest (instead of only underpowered loci) was performed using the 
meta R package and found substantial heterogeneity (I2 > 89%) driven by APOE, which 
represented almost 70% of the regression weights. As such, the P values for age-specific effects 
reported in the main text were Bonferroni-adjusted for a total of 12 statistical tests. 
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Associations with diseases and traits 
Lead SNPs from the multivariate GWAS and close proxies (r2EUR > 0.6) were looked up in the 
GWAS catalog54 and PhenoScanner55 (accessed 14 October 2019). All genome-wide 
associations were included except triallelic SNPs, associations without effect sizes, and 
associations with healthspan, lifespan, longevity, or medications. Similar traits were then 
grouped together using approximate string matching—verified manually—keeping only the 
strongest association and the shortest trait name. For example, Body mass index, Body mass 
index in smokers, and Body mass index in females greater than 50 years of age were grouped 
and renamed to Body mass index. Associations were then categorised into seven disease 
phenotypes based on keywords and manual curation: Cardiovascular, Metabolic, 
Neuropsychiatric, Immune-related, Smoking-related, Cancer, and Age-related. Cardiovascular 
phenotypes included lipid levels, vascular traits, and diseases concerning the heart; Metabolic 
phenotypes included body (fat) mass and glycaemic traits; Neuropsychiatric phenotypes 
included neurodegenerative diseases and disorders of brain signalling such as restless leg 
syndrome and epilepsy; Immune-related phenotypes included measures of immune cells, and 
inflammatory and autoimmune disorders; Smoking-related phenotypes included smoking and 
lung function-related traits; Cancer included all neoplasms and carcinomas; Age-related 
phenotypes included traits typically associated with advancing age, such as age at menopause, 
male pattern baldness, age-related macular degeneration, hearing loss, and frailty. See 
Supplementary Data 9 for a list of all phenotypes within each category. 
Gene expression colocalisation analysis 
For each locus of interest, gene expression was tested for colocalisation with SNP effects within 
500 kb of the lead SNP using SMR-HEIDI56,57. The gene expression studies included Westra 
(cis-eQTL), CAGE (cis-eQTL), Vosa (cis- and trans-eQTL), and GTEx v758–61, the latter with 
eQTL P < 10–5 only. Estimates of SNP effects are needed for SMR but are not directly provided 
by the multivariate analysis. Instead, we derived Z scores from multivariate P values and signed 
these based on the sign of the sum of underlying healthspan, parental lifespan, and longevity Z 
scores. The HEIDI statistic is dependent on the heterogeneity between effect estimates. We 
therefore recalculated standard errors and effect sizes based on allele frequency and sample 
size, using formula 6 from Zhu et al.56. For sample size, we used the sum of individual studies’ 
effective samples (N = 709,709) and performed a sensitivity test using the sum of all samples 
(regardless of their contribution to study power; N = 1,349,432). Differences in PHEIDI between 
analyses were <0.0006, i.e. had no practical effect on results. A Benjamini-Hochberg multiple 
testing correction was applied separately to each eQTL dataset to account for the number of 
genes tested. Determining an optimal threshold for heterogeneity pruning is less 
straightforward: Wu et al.57 consider 5% to be too conservative, especially when using 
summary-level data and SNPs with different sample sizes, and set a 1% threshold to correct for 
three colocalisation tests. We apply the same threshold, which may still be conservative in our 
study as we test many (albeit partially overlapping) tissues and we expect additional 
heterogeneity due to inferred Z scores (see Discussion). 
Gene set enrichment analysis 
Genes colocalising with loci of interest in cis or trans at FDR < 5% were tested for enrichment 
in 50 GO hallmark and 7350 biological process gene sets from the Molecular Signatures 
Database33, using a procedure analogous to Gene2Func in FUMA62. First, we translated all 
unique gene symbols from the eQTL datasets to Entrez IDs (N = 24,670), and subsetted 
hallmark and GO biological process gene sets to only include genes for which eQTL were 
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available. We then used a hypergeometric test to assess whether our genes were overrepresented 
in each pathway compared to all genes with eQTL. A minimum of three genes had to be present 
in a gene set for it to be tested for enrichment. Seven hallmark gene sets and 383 biological 
process gene sets met this requirement. Bonferroni correction was applied to account for 
multiple testing, separately for hallmark and biological process sets. Gene sets with Pbonferroni < 
5% are reported. 
Mendelian randomisation analysis 
Summary statistics for serum iron, ferritin, transferrin, and transferrin saturation were obtained 
from Benyamin et al.18 to be used as exposures in a Mendelian randomisation (MR) analysis. 
Univariate MR was performed using the R package TwoSampleMR63, with instrumental 
variables defined as the lead genome-wide significant SNPs (P < 5x10–8; at least 1 Mb apart) 
shared between each iron-related trait and our meta-analysis (Niron = 6; Nferritin = 5; Ntransferrin = 
11; Nsaturation = 9). We calculated the effect estimates of our multivariate meta-analysis using 
the same method as described for SMR-HEIDI. For each iron-related trait, two inverse 
variance-weighted regressions were run with the iron-related trait as exposure and the inferred 
multivariate effect sizes as outcome: one without a fixed intercept to test for pleiotropy violation 
(MR Egger) and one with the intercept set to zero. We adjusted P values for multiple testing 
using the Benjamini-Hochberg method with an FDR threshold of 5% for significance. We also 
performed a leave-one-out analysis to assess whether the observed effects were robust to 
outliers. 
Multivariate MR was performed using the R package MendelianRandomization64, which could 
fit a random-effects model and provides an estimate of the multivariate regression intercept but 
is otherwise identical to TwoSampleMR. As instrumental variables, we used the same iron trait-
related lead SNPs as before, keeping only the SNP with the strongest association if multiple 
lead SNPs were located in the same 1 Mb locus (N = 15). We fitted a random-effects, inverse 
variance-weighted model, with and without fixed intercept, with the multivariate ageing trait as 
outcome, and as before, performed a sensitivity analysis using the leave-one-out method. The 
main analysis was then repeated using the same SNPs and effects derived from the original 
healthspan, lifespan, and longevity GWAS as outcomes. P values were adjusted for eight tests 
(four traits, with and without intercept) using the Benjamini-Hochberg method. 
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